<DOC>
	<DOCNO>NCT02531815</DOCNO>
	<brief_summary>This Phase 1 first-in-human single ascend dose study randomize , double-blind , placebo-controlled investigation safety , tolerability , pharmacokinetics , pharmacodynamics PF-06741086 .</brief_summary>
	<brief_title>Dose Escalation Study PF-06741086 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) 100 kg ( 220 lb ) . Increased risk thrombosis ( coronary artery disease , hypercholesterolemia , diabetes ) Use nicotine/tobacco product Clotting disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Phase 1</keyword>
	<keyword>first human</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>tissue factor pathway inhibitor</keyword>
	<keyword>japanese</keyword>
</DOC>